Quinn Opportunity Partners LLC Has $3.35 Million Holdings in Illumina, Inc. $ILMN

Quinn Opportunity Partners LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 63.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 35,264 shares of the life sciences company’s stock after selling 62,423 shares during the quarter. Quinn Opportunity Partners LLC’s holdings in Illumina were worth $3,349,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Quent Capital LLC acquired a new position in shares of Illumina during the 3rd quarter valued at $29,000. Aster Capital Management DIFC Ltd acquired a new stake in Illumina in the third quarter worth $33,000. Mather Group LLC. acquired a new stake in Illumina in the third quarter worth $46,000. Evelyn Partners Investment Management LLP increased its stake in Illumina by 4,927.3% in the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares in the last quarter. Finally, SJS Investment Consulting Inc. increased its stake in Illumina by 13,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 529 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.60% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $118.94 on Friday. The stock has a market cap of $18.19 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 2.21 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The firm’s 50-day simple moving average is $133.15 and its 200 day simple moving average is $119.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. JPMorgan Chase & Co. decreased their target price on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Canaccord Genuity Group upped their price target on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, January 26th. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Finally, Barclays raised their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.